Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
PIM2 encodes a protooncogene that acts as a serine/threonine protein kinase. De plus, nous expédions Proto-Oncogene Pim-2 (Serine Threonine Kinase) Protéines (17) et Proto-Oncogene Pim-2 (Serine Threonine Kinase) Kits (13) et beaucoup plus de produits pour cette protéine.
Showing 10 out of 112 products:
Human Polyclonal PIM2 Primary Antibody pour ICC, IF - ABIN4345625
Santio, Vahakoski, Rainio, Sandholm, Virtanen, Prudhomme, Anizon, Moreau, Koskinen: Pim-selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion. dans Molecular cancer 2010
Show all 2 Pubmed References
Human Polyclonal PIM2 Primary Antibody pour ELISA, WB - ABIN4345627
Morishita, Katayama, Sekimizu, Tsuruo, Fujita: Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. dans Cancer research 2008
Human Polyclonal PIM2 Primary Antibody pour ELISA, WB - ABIN4345628
Hammerman, Fox, Cinalli, Xu, Wagner, Lindsten, Thompson: Lymphocyte transformation by Pim-2 is dependent on nuclear factor-kappaB activation. dans Cancer research 2004
Human Polyclonal PIM2 Primary Antibody pour IHC (p), IP - ABIN392442
Pogacic, Bullock, Fedorov, Filippakopoulos, Gasser, Biondi, Meyer-Monard, Knapp, Schwaller: Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. dans Cancer research 2007
Inhibition of the Pim1 (Montrer PIM1 Anticorps) oncogene (Montrer RAB1A Anticorps) results in diminished visual function.
show that PIM1 (Montrer PIM1 Anticorps) contributes to melanoma cell proliferation and tumor growth in vivo; however, the presence of PIM2 and PIM3 (Montrer PIM3 Anticorps) could also influence the outcome.
the elevated expression of PIM2 in blastic cells is associated with poor prognosis of AML (Montrer RUNX1 Anticorps) patients and their resistance to induction therapy.
Our data provide evidence for a novel role for Pim2 in the regulation of the DNA damage response (DDR (Montrer DDR1 Anticorps)). Knockdown of Pim2 upregulates several downstream DDR (Montrer DDR1 Anticorps) markers, mimicking the effects of doxorubicin (Dox) treatment of MM cells, and suggesting a role for the kinase as a negative regulator of this pathway.
These results demonstrate the involvement of PIM (Montrer PIM1 Anticorps) kinases in LIF (Montrer LIF Anticorps)-induced regulation in different trophoblastic cell lines which may indicate similar functions in primary cells.
PIM (Montrer PIM1 Anticorps) kinases in classical Hodgkin lymphoma exhibit pleiotropic effects, orchestrating tumor immune escape and supporting Reed-Sternberg cell survival.
High PIM2 expression is associated with osteosarcoma.
We show that Pim2 inhibitors and proteasome inhibitors, such as bortezomib, have additive effects to inhibit the growth of myeloma cells, suggesting that Pim2 could be an interesting target for the treatment of multiple myeloma.
PIM2 gene knockdown enhances the anti-proliferative effect of AZD1208 in non-Hodgkin lymphoma cell line.
A high percentage of urothelial carcinomas express Pim (Montrer PIM1 Anticorps) kinases. Pim (Montrer PIM1 Anticorps) expression differs in NILG, NIHG, and IHG lesions.
Our findings suggest that Pim-2-mediated aerobic glycolysis is critical for monitoring Warburg effect in colorectal tumor cells, highlighting Pim-2 as a potential metabolic target for colorectal tumor therapy.
studies define a pathway for limiting the regulation of Foxp3 (Montrer FOXP3 Anticorps) function because the Pim-2 kinase represents a potential therapeutic target for modulating the Treg cell suppressive activities in controlling immune responses
Pim2 facilitated allograft rejection primarily by modulating the apoptosis of effector T cells and the function of regulatory T cells.
Loss of PIM2 is associated with abnormal hematopoietic phenotypes.
signals from IL-7 (Montrer IL7 Anticorps) and RAG DSBs activate distinct Pim (Montrer PIM1 Anticorps) kinase family members that have context-dependent activities in regulating pre-B cell proliferation and survival.
Targeting cap-dependent translation blocks converging survival signals by AKT (Montrer AKT1 Anticorps) and PIM 1 (Montrer PIM1 Anticorps), 2 kinases in lymphoma
PIM2 controls the expression of the pro-inflammatory cytokine IL-6 (Montrer IL6 Anticorps).
results support the hypothesis that Pim2, which is also a known target of Flt3 (Montrer FLT3 Anticorps)-ITD (another gene that cooperates with PML (Montrer PML Anticorps)-RARalpha (Montrer RARA Anticorps)), cooperates with PRalpha to induce acute promyelocytic leukemia (Montrer PML Anticorps)-like disease
Pim-2 is a direct link between growth factor-induced transcription and a novel, kinase-dependent pathway that promotes cell-autonomous survival
pim-2 functions similarly to pim-1 (Montrer PIM1 Anticorps) as a pro-survival kinase; BAD is a legitimate PIM-2 substrate
Pim-2 and Akt-1 (Montrer AKT1 Anticorps) are critical components of overlapping but independent pathways, either of which is sufficient to promote the growth and survival of nontransformed hematopoietic cells
This gene encodes a protooncogene that acts as a serine/threonine protein kinase. Studies determined the encoded protein functions to prevent apoptosis and to promote cell survival.
, proviral integration site 2
, serine/threonine-protein kinase Pim-1
, serine/threonine-protein kinase pim-2
, proto-oncogene Pim-2 (serine threonine kinase)
, serine/threonine protein kinase pim-2
, serine/threonine kinase